Arthneeti
Latest: Hikal Ltd Q1 FY27 (Apr–Jun 2026) results →This page is Q4 FY26 (Jan–Mar 2026).All Q4 FY26 results →
H

Hikal Ltd

Q4 FY26Pharmaceuticals & Biotechnology

Hikal Q4 FY26 earnings call: Revenue & Margins

Q4 FY26 earnings call: what management said on revenue, margins and capex.

Price₹216
Market cap₹2.7K Cr
P/E63.4
Updated23 Aug 2026
Read4 min read

What the Q4 FY26 call signalled

1 of 3 strong

RevenueSlow growth
MarginMargins steady
CapexCapex planned

The short version

Hikal expects growth to resume from FY '27 onwards after a challenging FY '25 and FY '26, with medium to long-term revenue growth visibility intact. Hikal expects growth to resume from FY '27 onwards after a challenging FY '25 and FY '26, with plans intact despite a 2-3 year delay.

From Hikal Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

Slow growth
  • Hikal expects growth to resume from FY '27 onwards after a challenging FY '25 and FY '26, with medium to long-term revenue growth visibility intact.
  • Animal Health business is projected to scale meaningfully over several years, supported by commercialization of existing programs and new CDMO opportunities.
  • Crop business volume growth is positive but expected to be modest; growth will mainly come from Pharma, Animal Health, and Specialty Chemicals divisions.
  • The company aims for a top-line business of INR 500 crores plus in Animal Health within 4-5 years.

2 more points from Hikal Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Hikal Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned
  • Significant investment of about INR900 crores over the last 4 years, with INR600 crores in growth capex and INR300 crores in infrastructure and regulatory/maintenance capex.
  • INR300 crores growth capex invested in multipurpose assets being retooled for Pharma and Animal Health business.
  • New high-potency laboratory and expanded R&D center in Pune operational to enhance complex chemistry capabilities.
  • New pilot plant at U.S. FDA-approved Panoli facility to support growth.
  • Planned HPAPI manufacturing facility in Pune targeted for FY '28.
  • FY '26 capital expenditure of INR149 crores for debottlenecking, regulatory upgrades, and expanding CDMO capacities.
  • Strategic investments made in the last 12-15 months becoming operational to support next phase of growth.

2 more points from Hikal Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1KRM Ayurveda
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Hikal Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • The order book for Hikal Limited remains intact despite recent challenges.
  • There was a loss of business in Q4 due to FDA-related slowdowns, but recovery is expected in the next few quarters.
  • CDMO segment continues to have long-term orders and engagements.
  • Animal Health business is progressing well with validated products moving into the commercial phase.
  • Encouraging inquiries and RFPs received from global customers, indicating a strong commercial pipeline.

2 more points from Hikal Ltd's call on order book

Create a free account to keep reading this call

Hikal Ltd — Quarterly revenue & net profit

Revenue Net profit Net loss
Dec 2024Q3 FY25
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26

Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹519 Cr, net profit ₹14 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Hikal's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Balaxi Pharma (Q4 FY26)

    Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY

  • Accretion Pha. (Q4 FY26)

    45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks

  • Guj. Themis Bio. (Q4 FY26)

    . Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.

  • Aptus Pharma (Q4 FY26)

    The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharma.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Hikal Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Hikal Ltd Q4 FY26 results?

Hikal expects growth to resume from FY '27 onwards after a challenging FY '25 and FY '26, with medium to long-term revenue growth visibility intact. Hikal expects growth to resume from FY '27 onwards after a challenging FY '25 and FY '26, with plans intact despite a 2-3 year delay.

What is Hikal Ltd share price analysis?

Hikal Ltd currently shows a neutral. The stock trades at a P/E of 63.4 with a market cap of ₹2,688 Cr. Investors should review the full earnings analysis for detailed insights.

Is Hikal Ltd planning capital expenditure?

Significant investment of about INR900 crores over the last 4 years, with INR600 crores in growth capex and INR300 crores in infrastructure and regulatory/maintenance capex. - INR300 crores growth capex invested in multipurpose assets being retooled for Pharma and Animal Health business. - New high-potency laboratory and expanded R&D center in Pune operational to enhance complex chemistry capabilities. - New pilot plant at U.S.

Keep Hikal Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.